Electromag
Brushless BLDC Motors for Medical Devices
The European Medicines Agency (EMA) has granted orphan drug status to OctreoPharm Sciences' SOMscan, used for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.
The European Medicines Agency (EMA) has granted orphan drug status to OctreoPharm Sciences’ SOMscan, used for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.
The new Gallium-68-labeled radioactive contrast agent for PET has the potential to detect Phase I neuroendocrine tumours.
SOMscan binds to four out of five specific tumour receptor subtypes, which may allow detection of tumours that previously escaped discovery in imaging.
Brushless BLDC Motors for Medical Devices
Hydrophilic and Hydrophobic Treatments and Coatings for the Medical Industry
Components for Medical Devices